Fluoxetine Reduced Depression, Alcohol, and Marijuana Use in Suicidal Substance Abusers | Research

The takeaway

In one of the only controlled studies of suicidal substance abusers, fluoxetine decreased depression, suicidal ideation, alcohol consumption, and marijuana use, with benefits persisting at one-year follow-up.

Read this if you work with patients who have co-occurring substance use, depression, and suicidal ideation.

90% of patients had suicidal ideation, yet treatment improved multiple outcomes

What the researchers found

Studies of suicidal substance abusers are extremely rare because suicidality is typically an exclusion criterion for treatment studies. This review described one of the only double-blind, placebo-controlled studies addressing this population.

The study involved 51 patients with comorbid major depression and alcohol dependence, of whom 39% had attempted suicide in the current episode, 61% had a lifetime attempt, and 90% reported suicidal ideation. Fluoxetine decreased both depressive symptoms (including suicidal ideation) and alcohol consumption, though it did not eliminate either problem entirely.

Secondary analyses revealed additional findings: fluoxetine also significantly reduced marijuana use in a subgroup with cannabis abuse, and the magnitude of improvement was described as "robust." The benefits of fluoxetine for depression and drinking persisted at one-year follow-up. However, cocaine abuse predicted poor outcomes for both depression and alcohol use.

Why it matters

This is one of the very few studies to include suicidal substance users, who are normally excluded from treatment research. The finding that treating depression with fluoxetine also improved substance use, including marijuana, supports the importance of treating psychiatric comorbidities alongside substance use disorders.

The numbers in context

51 patients in controlled study. 39% current suicide attempt. 61% lifetime attempt. 90% suicidal ideation. Fluoxetine reduced depression, suicidal ideation, alcohol, and marijuana use. Cocaine predicted poor outcome.

How the study worked

Review of one open-label study (12 patients) and one double-blind placebo-controlled study (51 patients) of fluoxetine in suicidal substance abusers, plus secondary analyses and one-year follow-up data.

What this study cannot tell us

Only one controlled study with 51 patients. The marijuana finding was a secondary analysis of a subgroup. Fluoxetine reduced but did not eliminate symptoms. The study population was specific (comorbid depression + alcohol dependence) and may not generalize.

How to read the evidence

One double-blind, placebo-controlled study with secondary analyses. Important for addressing an underserved population but limited by small sample and secondary analysis design.

When this study was published

Published in 2001. Treatment research on suicidal substance abusers remains limited, though this study demonstrated its feasibility.

The bigger picture

The exclusion of suicidal patients from treatment research has left a critical gap in understanding how to treat one of the highest-risk populations. This study demonstrated that treatment is both possible and effective, though more research is urgently needed.

Questions still open

Would newer antidepressants be more effective? Does treating depression reduce cannabis use through improved mood or through other mechanisms? Why does cocaine predict poor outcomes while marijuana does not?

Common questions

Did treating depression help with substance use?

Yes. Fluoxetine reduced both depressive symptoms and substance use (alcohol and marijuana), suggesting that treating the underlying depression can improve substance use outcomes.

Why are suicidal patients excluded from research?

Safety concerns and liability issues typically exclude suicidal patients from treatment studies, creating a gap in understanding how to treat this high-risk population.

Read the original research

Treating the substance-abusing suicidal patient.

Annals of the New York Academy of Sciences, 932, 78-90; discussion 91-3

View on PubMed ↗

Citation

Cornelius, J R; Salloum, I M; Lynch, K; Clark, D B; Mann, J J. (2001). Treating the substance-abusing suicidal patient.. Annals of the New York Academy of Sciences, 932, 78-90; discussion 91-3.